Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Group 1 - The upcoming Phase III trial for daraxonrasib, specifically the RASolute 302 study, is set to release top-line data in the first half of 2026, focusing on second-line PDAC treatment [1] - The study has dual primary endpoints of progression-free survival (PFS) and overall survival (OS), indicating that it could succeed based on either endpoint being positive, although it will be triggered by a specific number of OS events [1] - There is a question regarding the similarity of patients in the RASolute 302 study compared to the prior Phase I/II study, and the confidence in replicating the positive results from the earlier study in the larger Phase III trial [2]